SIC
AZN icon

SJS Investment Consulting’s AstraZeneca AZN Stock Holding History

SJS Investment Consulting’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.6K Buy
93
+89
+2,225% +$16.7K ﹤0.01% 840
2026
Q1 		$789 Sell
4
-59
-94% -$11.4K ﹤0.01% 1573
2025
Q4 		$11.5K Buy
63
+59
+1,475% +$10.3K ﹤0.01% 751
2025
Q3 		$614 Hold
4
– – ﹤0.01% 1165
2025
Q2 		$560 Hold
4
– – ﹤0.01% 1077
2025
Q1 		$588 Hold
4
– – ﹤0.01% 1193
2024
Q4 		$525 Hold
4
– – ﹤0.01% 1225
2024
Q3 		$624 Hold
4
– – ﹤0.01% 1251
2024
Q2 		$624 Buy
+4
New +$602 ﹤0.01% 1217

Other funds holding AZN

EPGL
Evelyn Partners Group Ltd London $46.9B AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
CDDEC
Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return

SJS Investment Consulting's AZN Position: Q2 2026 in Review

SJS Investment Consulting increased its AstraZeneca (AZN) stake by 2,225% in Q2 2026, buying an estimated $16.7K and bringing the position to 93 shares worth $17.6K. The position accounts for ﹤0.01% of the portfolio, ranked #840.

SJS Investment Consulting first reported a position in AZN in Q2 2024 and has held it in 9 quarters since. 977 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • SJS Investment Consulting held 93 shares of AstraZeneca worth $17.6K as of Q2 2026.
  • SJS Investment Consulting bought 89 AstraZeneca shares in Q2 2026, an estimated $16.7K.
  • AstraZeneca made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #840 holding.
  • SJS Investment Consulting first reported a position in AstraZeneca in Q2 2024 and has held it in 9 quarters since.
  • 977 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.